Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Treatment with Bitter Melon Juice Blocks Growth of Pancreatic Cancer Cells

By BiotechDaily International staff writers
Posted on 25 Mar 2013
Image: Momordica charantia (Photo courtesy of Sayat Arslanlioglu).
Image: Momordica charantia (Photo courtesy of Sayat Arslanlioglu).
Juice of the bitter melon (Momordica charantia), which has been used in natural Asian medicine for treatment of diabetes, was found to kill pancreatic cancer cells both in vitro and in vivo without noticeable toxicity to normal tissues.

Investigators at the University of Colorado (Aurora, USA) worked with cultures of the pancreatic cancer cell lines BxPC-3, MiaPaCa-2, AsPC-1, and Capan-2 and with a xenograft model of MiaPaCa-2 tumors growing in nude mice. The cell cultures were treated with bitter melon juice while the mice were fed lyophilized bitter melon juice for a period of six weeks.

Results published in the March 8, 2013, online edition of the journal Carcinogenesis revealed that bitter melon juiced decreased cell viability in all four pancreatic carcinoma cell lines by inducing strong apoptotic death. Oral administration of lyophilized bitter melon juice for six weeks inhibited MiaPaCa-2 tumor xenograft growth by 60% without noticeable toxicity in nude mice.

At the molecular level, bitter melon juice was shown to activate caspases and alter expression of Bcl2 family members and cytochrome-c release into the cytosol. Additionally, it decreased survivin and XIAP (X-linked inhibitor of apoptosis protein) but increased p21, CHOP (DNA-damage-inducible transcript 3), and phosphorylated MAPKs (ERK1/2 and p38) levels. In addition, bitter melon juice activated AMP-activated protein kinase (AMPK), a biomarker for cellular energy status. An AMPK inhibitor (Compound C) reversed bitter melon juice-induced caspase 3 activation, suggesting activated-AMPK involvement in the induced apoptosis.

Immunohistochemical analyses of MiaPaCa-2 xenografts showed that bitter melon juice inhibited proliferation, induced apoptosis, and activated AMPK in vivo.

“Three years ago researchers showed the effect of bitter melon extract on breast cancer cells only in a Petri dish. This study goes much, much farther. We used the juice—people especially in Asian countries are already consuming it in quantity. We show that it affects the glucose metabolism pathway to restrict energy and kill pancreatic cancer cells,” said senior author Dr. Rajesh Agarwal, professor of pharmaceutical sciences at the University of Colorado. “It is a very exciting finding. Many researchers are engineering new drugs to target cancer cells’ ability to supply themselves with energy, and here we have a naturally-occurring compound that may do just that.”

Related Links:
University of Colorado


Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.